Publications

09 Jan 2018
First Look

First Look at New Research and Ideas, January 9, 2018

type of entrepreneurial population studied (e.g., Main Street vs. those backed by venture capital) to identify interesting and irreducible parts of this heterogeneity, while also identifying places where we anticipate future large-scale View Details

Keywords: Sean Silverthorne

29 Aug 2017
First Look

First Look at New Research and Ideas, August 29

people imagining imminent death. Study 1 revealed that blog posts of near-death patients with cancer and amyotrophic lateral sclerosis were more positive and less negative than the simulated blog posts of nonpatients—and also that the... View Details

Keywords: Sean Silverthorne

10 Oct 2017
First Look

First Look at New Research and Ideas, October 10, 2017

therapies for a given disease and promised a number of efficiency improvements. They also used statistical techniques to allow more patients access to promising therapies. As such, they had the potential to fundamentally change the clinical View Details

Keywords: Sean Silverthorne

Article

One Obstacle to Curing Cancer: Patient Data Isn't Shared

By: Richard G. Hamermesh and Kathy Giusti

Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For... View Details

Keywords: Healthcare; Technological And Scientific Innovation; Cancer Care In The U.S.; Cancer Treatment; Precision Medicine; Personalized Medicine; Data Sharing; Technological Innovation; Analytics and Data Science; Health Disorders; Medical Specialties; Research and Development; Customization and Personalization; Health Industry; United States

Register to Read

May–June 2018
Article

Data Uncertainty in Markov Chains: Application to Cost-Effectiveness Analyses of Medical Innovations

By: Joel Goh, Mohsen Bayati, Stefanos A. Zenios, Sundeep Singh and David Moore

Cost-effectiveness studies of medical innovations often suffer from data inadequacy. When Markov chains are used as a modeling framework for such studies, this data inadequacy can manifest itself as imprecision in the elements of the transition matrix. In this paper,... View Details

Keywords: Markov Chains; Cost Effectiveness; Medical Innovations; Colorectal Cancer; Health Care and Treatment; Cost vs Benefits; Innovation and Invention; Mathematical Methods; Health Industry

Find at Harvard

October 2013
Case

FasterCures: Removing Barriers to Treatments

By: Richard G. Hamermesh and James Weber

In mid-2013, as FasterCures celebrated its 10th anniversary as a center of the Milken Institute, Executive Director Margaret Anderson thought about what the organization should do to ensure it had even more impact in its next 10 years. FasterCures was a non-profit... View Details

July 2021
Supplement

Adaptive Platform Trials: The Clinical Trial of the Future? (C)

By: Ariel D. Stern and Sarah Mehta

This (C) case provides an update on the work of the Global Coalition for Adaptive Research (GCAR) and also illustrates how adaptive platform trials can nimbly respond to a global pandemic. View Details

Keywords: Clinical Trials; Drug Trials; Drug Testing; Cancer Trials; Glioblastoma; Platform Trials; Adaptive Trials; Adaptive Platform Trials; Health Testing and Trials; Health Care and Treatment; Business Strategy; Health Industry; United States

February 1994 (Revised May 1999)
Case

Manville Corp. Fiber Glass Group (C)

By: Lynn S. Paine and Sarah Gant

Manville Corp.'s senior managers are surprised when Japanese government officials advise them not to go forward with their plan to add a cancer warning label to diatomaceous earth (DE) products sold in Japan. The International Agency for Research on Cancer has ruled... View Details

Keywords: Management Teams; Ethics; Conflict of Interests; Health; Safety; Cross-Cultural and Cross-Border Issues; Policy; Japan

December 2003
Case

Manville Corporation Fiber Glass Group (C) (Abridged)

By: Lynn S. Paine

Manville Corp.'s senior managers are surprised when Japanese government officials advise them not to go forward with their plan to add a cancer warning label to diatomaceous earth (DE) products sold in Japan. The International Agency for Research on Cancer has ruled... View Details

Keywords: Risk and Uncertainty; Moral Sensibility; Safety; Government Administration; Cross-Cultural and Cross-Border Issues; Decision Choices and Conditions; Ethics; Announcements; Industrial Products Industry; Japan

20 Sep 2011
First Look

First Look: September 20

on Cancer: Integrative Research Centers at the Dana Farber Cancer Institute Heidi K. Gardner, Edo Bedzra, and Shereef M. ElnahalHarvard Business School Case 412-029 Dr. Barrett Rollins, chief scientific... View Details

Keywords: Sean Silverthorne

30 Aug 2016
First Look

August 30, 2016

forthcoming Journal of Marketing Research Incentives versus Reciprocity: Insights from a Field Experiment By: Chung, Doug J., and Das Narayandas Abstract—We conduct a field experiment in which we vary the sales force compensation scheme... View Details

Keywords: Carmen Nobel

07 Jun 2016
First Look

June 7, 2016

strategic, financial, and operational objectives. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=51110 May 2016 Oncology How the Affordable Care Act Has Affected Cancer Care in the United States: Has Value for View Details

Keywords: Sean Silverthorne

September 2020
Case

Minerva 2010: Turbulent Times

By: John R. Wells and Benjamin Weinstock

In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at... View Details

Keywords: Biotechnology; Research; Product Development; Commercialization; Strategy